Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study.
about
Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the LiteratureBotulinum toxin A for the Treatment of Overactive BladderPractical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder SyndromeOnabotulinumtoxinA for the treatment of overactive bladderOnabotulinumtoxinA for the treatment of idiopathic overactive bladder is effective and safe for repeated use.Emerging treatments for overactive bladder: clinical potential of botulinum toxins.What is the feasibility of switching to 200IU OnabotulinumtoxinA in patients with detrusor overactivity who have previously received 300IU?How to define a refractory idiopathic overactive bladder?Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder SyndromeThe safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis.Use of onabotulinumtoxinA for overactive bladder with concomitant warfarin.Coining a new term-Urovesicology: advancing towards a mechanistic understanding of bladder symptoms.Efficacy of botulinum toxin type A 100 Units versus 200 units for treatment of refractory idiopathic overactive bladder.Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison.Eight-Year Experience With Botulinum Toxin Type-A Injections for the Treatment of Nonneurogenic Overactive Bladder: Are Repeated Injections Worthwhile?The use of botulinum toxin for the treatment of overactive bladder syndromeOveractive bladder - 18 years - Part IIMedium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder.Botulinum toxin injection for lower urinary tract dysfunction.Treatment of overactive bladder: what is on the horizon?Botulinum toxin treatment for bladder dysfunction.Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure.Intradetrusor onabotulinumtoxinA for overactive bladder.The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: A systematic review and meta-analysis.Current and potential urological applications of botulinum toxin A.Use of botulinum toxin for voiding dysfunction.Single-centre experience with intradetrusor injection of onabotulinumtoxinA: a retrospective study of the years 2003-2012 in a Danish population.Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015).Outcomes of intra-detrusor injections of botulinum toxin in patients with spina bifida: A systematic review.Abobotulinum - a toxin injection in patients with refractory idiopathic detrusor overactivity: injections in detrusor, trigone and bladder neck or prostatic urethra, versus detrusor - only injections.Patient factors associated with onabotulinum toxin A treatment outcome in women with detrusor overactivity.Conjoint Urological Society of Australia and New Zealand (USANZ) and Urogynaecological Society of Australasia (UGSA) Guidelines on the management of adult non-neurogenic overactive bladder.Impact of bladder dysfunction in the management of post radical prostatectomy stress urinary incontinence-a reviewDifferent number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: A prospective randomized comparative study.Diabetes mellitus does not affect the efficacy and safety of intravesical onabotulinumtoxinA injection in patients with refractory detrusor overactivity.A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages.Indirect treatment comparison (ITC) of medical therapies for an overactive bladder.Intermittent catheterisation after botulinum toxin injections: the time to reassess our practice.Comparison of the effectiveness of repeated injections of onabotulinum toxin A for refractory idiopathic detrusor overactivity: analysis of an open label extension of a randomized trial (the RELAX study).Therapeutic Approaches of Botulinum Toxin in Gynecology.
P2860
Q26749613-C53CFF07-A7F2-49CD-89B9-71EB2F664216Q26764765-1D5FAD4F-6569-4EC3-977D-463B743BB2A3Q26770415-EF77DD7E-B9C9-4266-B6BD-33A4124D50EDQ27002371-011DFEA5-AE68-4D1A-883B-B263EA4643AAQ33665035-56E57F16-F8CB-49D5-88FF-E56A28FCA023Q33689757-CD7ED6E1-2975-4E96-A608-6902F26340D9Q33819934-55695DB0-254F-4433-B1EE-0A36B6AAE13EQ35024928-B0448B04-79A7-486E-A9D9-B737962FF6BCQ35737565-C91A02CD-D6CC-4AF4-84EC-6AECD29347C1Q35798421-ADC71D7A-222D-4F76-ADA7-43314403957EQ36160965-C3B148F6-A418-4C0D-B034-53006B87D204Q36463541-2B37DE4E-B4F7-4691-AD57-119AEABB97FBQ36589242-6D6E743D-8154-4519-AA46-75E594F4F20CQ36625281-83A08A0D-C95C-41C2-B88E-F686138A2B05Q36760533-8DE565B4-6893-4ABB-AD71-7549B9AA6D85Q36830702-4780BC90-201B-4FBE-8A59-A771577E5352Q36912766-9A5BC7EE-E887-422D-AF53-FFFD0D9788D9Q37514596-DF232FBC-1807-487C-B407-31F12CB81A3BQ38008697-5A47F4C1-E6F4-40A7-96FB-FEE7DE9EA5C7Q38023204-1470D4FA-FF68-4DFA-9A73-B3C25D25540EQ38103282-5938AD71-6DC5-4554-8EF4-557A6C117D8DQ38182708-2CC7B891-A7FA-4CBB-A457-DCFB70191F29Q38198733-D07E5600-16F5-4678-ABA6-E3E9F7CE832BQ38200003-CCD20639-3A71-4AAD-9F52-30EB1EAEEE3FQ38564108-D905CA36-2535-4236-98E4-514AD9C23C8FQ38679555-CFC84AC0-F99E-459A-B4D0-03E3A6A7B525Q38682942-8DD2E0FC-21BA-4B7A-9823-B48FDDC2AD2BQ38819016-57E98680-BAD3-4044-89F3-D58802AB6917Q38836383-A818C466-4176-41D8-B5CB-A85CB494237FQ39152548-814CB77B-1CEB-486F-A5E7-EE3EDD5FE7AFQ40118662-48062D87-8E75-4FDB-AC50-D942AB636EA7Q40443607-99CCB37C-F6C6-458C-985A-1CCF4E85D303Q41096879-31F52E38-B36E-4025-B3E9-8B98DD875C3AQ41284362-4E927766-F3CD-448F-B3B0-C3518061FDFFQ44754205-34EA930C-29AA-4E1D-BB32-8E429FBF19C2Q45788137-A3B19578-B018-4255-802A-B81F188C7204Q47433658-9DC0A68B-B19E-4AC3-981D-60C34EFB6E68Q48012632-8996BE17-B216-4B23-9AA7-DEDED1A57E69Q51548888-49C92A52-1B00-41A6-B6E0-C291519C75DFQ52566035-2F67547D-6700-4A88-AA2C-79A830121015
P2860
Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Efficacy and safety of low dos ...... controlled dose-ranging study.
@en
Efficacy and safety of low dos ...... controlled dose-ranging study.
@nl
type
label
Efficacy and safety of low dos ...... controlled dose-ranging study.
@en
Efficacy and safety of low dos ...... controlled dose-ranging study.
@nl
prefLabel
Efficacy and safety of low dos ...... controlled dose-ranging study.
@en
Efficacy and safety of low dos ...... controlled dose-ranging study.
@nl
P2093
P1433
P1476
Efficacy and safety of low dos ...... controlled dose-ranging study.
@en
P2093
Christian Saussine
Emmanuel Chartier-Kastler
Frédéric Barbot
Gilles Karsenty
Gérard Amarenco
Idir Ghout
Jean-François Hermieu
Loïc Le Normand
Philippe Grise
Pierre Denys
P304
P356
10.1016/J.EURURO.2011.10.028
P407
P50
P577
2011-10-25T00:00:00Z